

NEWS

Contact
Gualberto Ruaño, M.D., Ph.D.
Genomas, Inc.
860.545.3773



FOR IMMEDIATE RELEASE
MAY 24, 2005

GENOMAS LAUNCHES LABORATORY OF PERSONALIZED HEALTH AND ANNOUNCES APPOINTMENT OF ITS PRESIDENT AS FELLOW OF THE NATIONAL ACADEMY OF CLINICAL BIOCHEMISTRY

HARTFORD, CT, Genomas, Inc., a leading biomedical company in personalized medicine announced today major milestones accelerating its entry into the diagnostic product market for precision treatment of obesity- and drug-induced metabolic syndromes. Product launches are planned for the fourth quarter of this year.

The company announced the final layout and full operation of its Laboratory of Personalized Health (LPH), a facility for clinical DNA testing. The LPH will advance to market diagnostic products containing proprietary genetic markers developed with the company's PhysioGenomics™ technology as well as licensed markers. The LPH is located within Genomas headquarters on the campus of Hartford Hospital. "The combination of clinical delivery and discovery of DNA markers within the same company is a unique and differentiating feature of our business model", said Gualberto Ruaño, M.D., Ph.D., President and CEO. "The LPH and our PhysioGenomics technology establish us as a very nimble business delivering personalized medicine today, while advancing the field through discovery programs. This dual capacity will allow the company to continue enhancing its leadership in the personalized healthcare industry."

Genomas announced that it has attained licensure of the LPH by the Connecticut Department of Public Health and its registration with the Centers for Medicare and Medicaid under CLIA (Clinical Laboratory Improvement Amendments). The license and registration now allow the company to perform high-complexity clinical DNA testing to support medical treatments and to seek reimbursement from Medicare and health insurance. LPH is a state-of-the-art facility utilizing microfluidic multi-analyte array technologies for parallel processing of several DNA markers. LPH is operated with systems, quality control and proficiency procedures utilized by all accredited clinical laboratories. LPH becomes one of the first clinical DNA testing centers in New England for generalized healthcare delivery. "With the licensure of LPH as a DNA clinical testing facility, the future of personalized medicine as well as drug safety is well on track for clinical investigation at Hartford Hospital", said Dr. Neil Yeston, Vice President Academic Affairs of Hartford Hospital.

The Company also announced the appointment of Dr. Ruaño, as a Fellow of the National Academy of Clinical Biochemistry (NACB). The NACB is the Academy of the American Association for Clinical Chemistry and is dedicated to advancing the science and practice of clinical laboratory medicine through research, education, and professional development (see <http://www.nacb.org>). It publishes Laboratory Medicine Practice Guidelines for the application of clinical biochemistry to medical diagnosis and therapy. In this capacity, Dr. Ruaño is serving as a member of the NACB committee developing "Guidelines and Recommendations for Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice", which are expected to be released in 2006. "Dr. Ruaño is a national thought leader in personalized medicine, and we are glad to count him as a major contributor to the NACB guidelines in pharmacogenetics", said Dr. Roland Valdes, Jr., Chairman of the NACB Committee

(more)

for the 2006 Guidelines on Pharmacogenetics, Professor of Pathology and Laboratory Medicine and Distinguished University Scholar at the University of Louisville School of Medicine, and Chief of Clinical Chemistry and Toxicology services at the University of Louisville Hospital. “Dr. Ruaño and his team are truly paving the way to the direct application of genetic information in patient healthcare”, indicated Dr. Valdes.

ABOUT GENOMAS

Genomas Inc. is a biomedical company advancing personalized medicine with revolutionary diagnostic PhysioType™ systems to treat obesity- and drug-induced metabolic syndromes in cardiovascular and psychiatric medicine. PhysioType systems provide physicians with the unprecedented capability to prescribe personalized drug treatments avoiding side effects and to recommend highly effective preventive exercise and diet programs for each patient. Genomas is located in Hartford, CT. on the campus of Hartford Hospital with which it has established a research and development partnership in genomic medicine. For more information please access the company’s web site at www.genomas.net

###